Stocks and Investing Stocks and Investing
Fri, March 17, 2023
Thu, March 16, 2023
Wed, March 15, 2023
Tue, March 14, 2023

Sumant Kulkarni Maintained (ACAD) at Strong Buy with Increased Target to $26 on, Mar 14th, 2023


Published on 2024-10-28 02:15:38 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Increased Target from $24 to $26 on, Mar 14th, 2023.

Sumant has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 4 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $19 on, Monday, March 13th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
  • Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023
  • Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022


This is the rating of the analyst that currently disagrees with Sumant


  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023